Ampel BioSolutions
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ampel BioSolutions sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Ampel BioSolutions: 3 sponsored US clinical trials, 1 recruiting.
Ampel BioSolutions sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupus Erythematosus, Systemic, with 1 trials.
Upper-quartile sponsor footprint
Ampel BioSolutions sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
NCT05845593
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
NCT03098823
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
NCT02598596
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Ampel BioSolutions pipeline
1 recruiting of 3 indexed (33% open); 2 completed (67%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Lupus Erythematosus, Systemic (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ampel BioSolutions: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Ampel BioSolutions sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Ampel BioSolutions page
3 registered trials is a research-attention snapshot, not an endorsement of Ampel BioSolutions or any single study.
- 1 of Ampel BioSolutions's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lupus Erythematosus, Systemic is the condition Ampel BioSolutions studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupus Erythematosus, Systemic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ampel BioSolutions pipeline card: 3 registered trials from official public datasets.Report a data error.